A study protocol for individualized prognostic counselling in the palliative phase
BMC Palliative Care,
Год журнала:
2025,
Номер
24(1)
Опубликована: Янв. 10, 2025
Язык: Английский
Evaluating the risk of comorbidity onset in elderly patients after a cancer diagnosis
BMC Public Health,
Год журнала:
2025,
Номер
25(1)
Опубликована: Фев. 17, 2025
Abstract
Background
Cancer
is
a
critical
disease
that
affects
person
physically,
mentally,
socially,
and
in
many
other
aspects.
During
the
treatment
stage
of
cancer,
patients
suffer
from
various
health
complexities,
especially
elderly
people,
which
might
result
onset
diseases
development
comorbid
condition.
Several
studies
have
shown
comorbidity
plays
crucial
role
cancer
survival.
However,
there
remains
lack
comprehensive
statistical
techniques
at
national
level
to
assess
significance
comorbidities
cancer.
Our
research
aims
address
this
gap
by
comparing
non-cancer
individuals
over
four
years’
time
period.
Methods
The
Health
Retirement
Study
(HRS)
data
was
used
extract
information
6651
participants
aged
more
than
50.
Within
4-year
span,
cross-sectional
observations
were
created
whether
or
not
based
on
such
as
high
blood
pressure,
diabetes,
heart
disease,
stroke,
lung
psychological
disease.
Results
In
multivariable
regression
model,
we
observed
higher
chances
developing
(OR
=
1.321,
p-value
0.0051)
among
group
compared
group,
adjusting
socio-economic
factors.
Moreover,
factors
found
be
significantly
associated
with
leading
applying
propensity
score
matching
(1:3
matching).
Finally,
balanced
also
showed
1.294,
0.0207)
patients.
Conclusions
above
findings
demonstrated
imperative
enhanced
protocols,
prioritize
overall
patients,
thereby
reducing
their
susceptibility
additional
illnesses.
Язык: Английский
Reflections on Electronic Health for Head and Neck Cancer—Insights Into Patient-Centered Palliative Care
JAMA Otolaryngology–Head & Neck Surgery,
Год журнала:
2025,
Номер
unknown
Опубликована: Апрель 10, 2025
Язык: Английский
Reflections on Electronic Health for Head and Neck Cancer—Insights into Patient-Centered Palliative Care—Reply
JAMA Otolaryngology–Head & Neck Surgery,
Год журнала:
2025,
Номер
unknown
Опубликована: Апрель 10, 2025
Язык: Английский
Electronic Health in the Palliative Care Pathway for Patients With Head and Neck Cancer
JAMA Otolaryngology–Head & Neck Surgery,
Год журнала:
2024,
Номер
unknown
Опубликована: Ноя. 14, 2024
The
Expert
Center
of
Palliative
Care
for
head
and
neck
cancer
offers
structural
attention
to
patients'
complex
physical
psychosocial
care
needs.
Patients
are
offered
remote
care,
including
digital
monitoring
using
patient-reported
outcome
measures,
enable
them
stay
as
long
possible
in
their
trusted
home
environment.
There
is
limited
literature
on
qualitative
feedback
experiences
with
palliative
especially
care.
To
provide
optimal
more
information
this
needed.
Язык: Английский
A phase II study of personalized ultrafractionated stereotactic adaptive radiotherapy for palliative head and neck cancer treatment (PULS-Pal): a single-arm clinical trial protocol
BMC Cancer,
Год журнала:
2024,
Номер
24(1)
Опубликована: Дек. 21, 2024
Abstract
Background
Many
patients
with
head
and
neck
cancer
are
not
candidates
for
standard
of
care
definitive
treatments
though
often
require
palliative
given
the
frequent
symptoms
associated
cancer.
While
existing
radiotherapy
regimens
can
provide
adequate
symptom
control,
they
have
limitations
particularly
respect
to
local
control
which
is
becoming
more
important
as
advances
in
systemic
therapy
improving
survival.
Personalized
ultrafractionated
stereotactic
adaptive
(PULSAR)
a
novel
regimen
leverages
treatment
technology
extended
interfraction
intervals
enable
possible
synergy
immune
system.
Additionally,
HyperArc©
(Varian
Medical
Systems,
Inc.)
planning
software
allows
safe
dose-escalation
tumors.
Methods
This
single-arm
phase
II
study
will
prospectively
evaluate
PULSAR
Patients
de
novo
or
recurrent,
localized
metastatic,
who
ineligible
decline
eligible
enrollment.
Forty-three
receive
an
11
Gray
fraction
radiation
every
two
weeks
total
five
fractions
dose
55
Gy.
Adaptive
permitted.
A
safety
feasibility
evaluation
be
performed
after
enrollment
first
fifteen
whereby
trial
closed
if
experience
CTCAEv5.0
grade
3
4
any
patient
experiences
5
toxicity
probably
attributable
during
within
three
months
its
completion.
The
primary
endpoint
one-year
tumor
control.
Secondary
endpoints
include
safety,
disease
progression-free
overall
survival,
symptomatic
impact,
frequency
re-simulation
and/or
planning,
dosimetry
PULSAR.
enrolled
permitted
cancer-directed
therapy,
including
immunotherapy,
may
allow
analysis
efficacy
this
combination.
Discussion
PULS-Pal
prospective
We
hypothesize
that
lead
improved
compared
historical
controls
undergoing
Trial
registration
Clinicaltrials.gov
identifier:
NCT06572423
.
Date
registration:
August
28th,
2024.
Язык: Английский
Evaluating the Risk of Comorbidity Onset in Elderly Patients After a Cancer Diagnosis
Research Square (Research Square),
Год журнала:
2024,
Номер
unknown
Опубликована: Дек. 16, 2024
Abstract
Background:
Cancer
is
a
critical
disease
that
affects
person
physically,
mentally,
socially,
and
in
many
other
aspects.
During
the
treatment
stage
of
cancer,
patients
suffer
from
various
health
complexities,
especially
elderly
people,
which
might
result
onset
diseases
development
comorbid
condition.
Several
studies
have
shown
comorbidity
plays
crucial
role
cancer
survival.
However,
there
remains
lack
comprehensive
statistical
techniques
at
national
level
to
assess
significance
comorbidities
cancer.
Our
research
aims
address
this
gap
by
comparing
non-cancer
individuals
over
four
years’
time
period.
Methods:
The
Health
Retirement
Study
(HRS)
data
was
used
extract
information
6651
participants
aged
more
than
50.
Within
4-year
span,
cross-sectional
observations
were
created
whether
or
not
based
on
such
as
high
blood
pressure,
diabetes,
heart
disease,
stroke,
lung
psychological
disease.
Results:
multivariable
logistic
regression
model,
we
observe
higher
chances
developing
(OR=1.321,
p-value
0.0051)
among
group
compared
group,
adjusting
socio-economic
factors.
Moreover,
factors
found
be
significantly
associated
with
leading
applying
propensity
score
matching
(1:3
matching).
Finally,
balanced
also
showed
(OR=1.294,
0.0207)
patients.
Conclusions:
above
findings
demonstrated
imperative
enhanced
protocols,
prioritize
overall
patients,
thereby
reducing
their
susceptibility
additional
illnesses.
Язык: Английский
A phase II study of personalized ultrafractionated stereotactic adaptive radiotherapy for palliative head and neck cancer treatment (PULS-Pal): a single-arm clinical trial protocol
Research Square (Research Square),
Год журнала:
2024,
Номер
unknown
Опубликована: Окт. 17, 2024
Abstract
Background:
Many
patients
with
head
and
neck
cancer
will
not
be
candidates
for
standard
of
care
definitive
treatments
though
often
require
palliative
given
the
frequent
symptoms
associated
cancer.
While
existing
radiotherapy
regimens
can
provide
adequate
symptom
control,
they
have
limitations
particularly
respect
to
local
control
which
is
becoming
more
important
as
advances
in
systemic
therapy
are
improving
survival.
Personalized
ultrafractionated
stereotactic
adaptive
(PULSAR)
a
novel
regimen
leverages
treatment
technology
extended
interfraction
intervals
enable
possible
synergy
immune
system.
Additionally,
HyperArc©
(Varian
Medical
Systems,
Inc.)
planning
software
allows
safe
dose-escalation
tumors.
Methods:
This
single-arm
phase
II
study
prospectively
evaluate
PULSAR
HyperArc
Patients
de
novo
or
recurrent,
localized
or
metastatic,
who
ineligible
decline
eligible
enrollment.
Forty-three
receive
an
11
Gray
fraction
radiation
every
two
weeks
total
five
fractions
dose
55
Gy.
Adaptive
permitted.
A
safety
feasibility
evaluation
performed
after
enrollment
first
fifteen
whereby
trial
continue
if
less
than
experience
CTCAEv5.0
grade
3
higher
toxicity
definitely
attributable
during
within
thirty
days
its
completion.
The
primary
endpoint
one-year
tumor
control.
Secondary
endpoints
include
safety,
disease
progression-free
overall
survival,
symptomatic
impact,
frequency
re-simulation
and/or
planning,
dosimetry
PULSAR.
enrolled
permitted
immunotherapy
PULSAR,
may
allow
analysis
efficacy
this
combination.
Discussion:
The
PULS-Pal
prospective
We
hypothesize
that
lead
improved
compared
historical
controls
undergoing
Trial
Registration:
Clinicaltrials.gov
identifier:
NCT06572423.
Date
registration:
August
28th,
2024.
https://clinicaltrials.gov/study/NCT06572423.
Язык: Английский
Current situation and influencing factors of palliative care practice ability among oncology nurses: A multicenter cross-sectional study
International Journal of Nursing Sciences,
Год журнала:
2024,
Номер
12(1), С. 35 - 41
Опубликована: Дек. 12, 2024
The
study
aimed
to
survey
the
current
situation
and
explore
factors
that
influence
ability
of
palliative
care
practice
among
oncology
nurses.
A
multicenter
cross-sectional
was
conducted
using
stratified
random
sampling
select
26
tertiary
hospitals'
departments
in
Hubei
Province,
China.
total
1,198
nurses
were
included
finished
questionnaire
consisting
social
demographic
characteristics,
Palliative
Care
Self-Report
Practice
Scale
(PCPS),
End-of-life
Professional
Caregiver
Survey
(EPCS),
Self-Perceived
Pain
Assessment
Knowledge
Confidence
(Self-PAC)
through
online
platform.
Data
analyzed
t-test,
one-way
ANOVA,
Pearson
correlation
analysis,
multiple
linear
regression
analysis
SPSS
26.0.
score
for
PCPS
67.17
±
12.57,
three
dimensions'
scores
were:
physical
symptom
(32.50
6.10),
spiritual
psychological
(23.35
4.97),
communication
(11.58
2.48).
There
are
significant
positive
correlations
between
core
competence
(r
=
0.77,
P
<
0.01),
as
well
pain
assessment
0.56,
0.01).
Multiple
identified
female,
with
high
education
background
(bachelor's
degree
master's
or
above),
interest
care,
ability,
predictors
(Adjusted
R
2
0.668,
0.05).
overall
relatively
high,
but
reported
suboptimal
performance
dimension
nursing
ability.
To
comprehensively
improve
nurses'
managers
must
consider
gender
structure,
educational
background,
enthusiasm
work,
competence,
Язык: Английский
The role of cetuximab in treatment of squamous cell carcinoma of the head and neck
Meditsinskiy sovet = Medical Council,
Год журнала:
2024,
Номер
21, С. 30 - 40
Опубликована: Дек. 21, 2024
Squamous
cell
carcinoma
of
the
head
and
neck
(SCCHN)
is
one
causes
cancer
mortality.
The
mortality
rate
patients
within
a
year
from
moment
diagnosis
reaches
27%
in
with
tumors
oral
cavity
35.2%
pharynx.
Despite
visual
localization
SCCHN
more
than
50%
at
time
are
not
subject
to
radical
surgical
treatment.
More
half
develop
relapses
3
years
after
end
Most
receive
antitumor
drug
therapy
either
when
an
unresectable/metastatic
tumor
detected
or
relapse
develops
previously
performed
Epidermal
growth
factor
receptor
(EGFR)
expressed
almost
100%
its
expression
generally
associated
decreased
overall
survival
progression-free
survival.
EGFR
target
for
targeted
drugs.
Cetuximab
monoclonal
antibody
that
blocks
EGFR.
review
examines
role
cetuximab
treatment
recurrent
and/or
metastatic
combination
chemotherapy
radiation
therapy.
main
undesirable
phenomenon
dermatological
toxicity:
acne-like
rash,
dry
skin,
paronychia.
Preventive
therapy,
including
antibiotic
doxycycline,
avoids
development
toxicity
2–3
degrees.
One
most
important
biological
processes
involved
progression
escape
immune
response
programmed
death
1
(PD-1),
which
inhibits
anti-tu
mor
response.
Immunotherapy
checkpoint
inhibitors
pembrolizumab
nivolumab
has
shown
significant
improvement
progressing
inclusion
cisplatin.
Pembrolizumab
cytostatics
effective
first-line
regimen
presence
PD-L1
(CPS
≥
1).
In
approximately
10–20%
patients,
changes
due
poor
tolerability.
Timely
prevention
relief
adverse
events,
control
disease
manifestations,
multidisciplinary
approach
patient
make
it
possible
achieve
optimal
results.
Язык: Английский